AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 20 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Infants who received meningococcal C conjugate (Men C) vaccinations possessed high antibody levels at the age of 4 years, according to a report in the Pediatric Infectious Disease Journal.
"Meningococcal C conjugate (Men C) vaccines have been routinely used in the U.K. since November, 1999," explained Jodie McVernon and colleagues at John Radcliffe Hospital in Oxford and Chiron Corp. "Little information exists regarding antibody persistence or immunologic memory after infant vaccination or response to a first dose at 4 years."
The investigators measured serum bactericidal activity (SBA) and the levels of IgG antibodies specific for Men C in 95 children who received Men C vaccinations as infants and were then immunized with Men C at the age of 4 years and in 103 control children matched for age (Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy 4-year-old children. Pediatr Infect Dis J, 2002;21(8):747-753).
McVernon and her collaborators found that 87% of the children who received at least three doses of Men C as infants demonstrated strong baseline SBA compared with only 21% of the nonimmunized controls. In addition, the children who received four Men C doses in infancy and were boosted at the age of 4 years had a significantly higher SBA than did the 4-year-old control children who received ...